Conduct↦Statistic Methodology↦Interim Analysis↦Procedures
Was betrifft es? Warum ist das wichtig?
During study conduct, Interim Analyses (IA) are performed as described in the study protocol and, if applicable, in the Statistical Analysis Plan (SAP).
The results of an IA may trigger a re-evaluation of the ongoing study. Aspects to consider include:
- Futility: A high likelihood that the intervention is ineffective or has only minimal benefit
- Safety: Unacceptable safety risks to participants (e.g. an unacceptable risk-benefit ratio)
- Efficacy: A significant beneficial treatment effect with study success being declared early
The expert consultation of an Independent Data Monitoring Committee (IDMC) (i.e. also called Data Safety Monitoring Board (DSMB) – focuses on safety) can advise the SP-INV on how to proceed with the study.
Conclusion could be that:
- Participant safety continues to be guaranteed (e.g. few adverse events), and the study can continue
- Safety concerns outweigh study benefits (i.e. a negative shift in the risk-benefit-ratio of the study), requiring that the study be stopped
Was muss ich befolgen?
As a SP-INV:
- Perform IA(s) as described in the study protocol and, if applicable, the SAP
- Ask the statistician to forward the results of the IA to the IDMC/DSMB for assessment
- In the event of a blinded study, ensure the blind is not broken during the analysis. In the event results indicate futility, safety or efficacy concerns, allow IDMC/DSMB to assess the data unblinded (i.e. the identification of the intervention and control group)
- Make informed decisions regarding the continuation of the study, based on IDMC/DSMB recommendations (e.g. early termination, changes to study inclusion/exclusion criteria, sample size adjustments)
Note: The introduction of additional (not-planned) IAs or the omission of a planned IA, requires a protocol amendment. An amendment must be approved by the Ethics Committee (EC) and, if applicable, RA (e.g. Swissmedic for risk-category B and C studies)
Wo kann ich Hilfe anfordern?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
CH GCP E6(R3) – see in particular
- Glossary: Definition interim clinical trial
- Essential records table: Interim and final clinical reports
- 3.16.1p,q Data handling and data analysis
- 3.16.2a Study report
- B10.1 Statistical considerations
- C.3s Essentiality of trials records
ICH Topic E9 – see in particular
- 4 Trial conduct considerations
- 4.1 Trial monitoring and interim analysis
- 4.2 Changes in inclusion and exclusion criteria
- Sample size adjustments
- 4.5 Interim Analysis and early stopping
- 4.6 Role of IDMC
- 7.1 Evaluation and reporting
ICH Topic E8(R1) General considerations for clinical studies - see in particular
- 6.1.4 Access to interim data
Swiss Law
ClinO – see in particular article
- Art. 2b Definition of intervention
ClinO-MD – see in particular article
- Art. 2a Definition of clinical intervention
- Art. 2a Definition of performance study
HRO – see in particular article
- Art. 3a Definition of research